CytoMed (NASDAQ: GDTC) stock is down 33% over the last 24 hours. GDTC stock fell in a mixture of real trading time, the aftermarket and now this morning. The reason for the decline is simply that it ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

CytoMed (NASDAQ: GDTC) stock is up 100%. The rise in GDTC stock seems to be coming from the award of a patent. This is a very silly idea, quite ridiculous. Of course, it's just great for those who ...

Short interest in CytoMed Therapeutics Ltd (NASDAQ:GDTC) decreased during the last reporting period, falling from 65.20K to 56.79K. This put 1.73% of the company's publicly available shares short.

Detailed price information for Cytomed Therapeutics Limited (GDTC-Q) from The Globe and Mail including charting and trades.

Nasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets. Analysts evaluate the stock’s expected performance in a given time period based on their ...

GDTC is trading in the middle of its 52-week range and below its 200-day simple moving average. Price change The price of GDTC shares has decreased $0.03 since the market last closed. This is a 2.47% ...